Aspirin resistance following pediatric cardiac surgery

• Published in: Thrombosis research Vol. 126; no. 3; pp. 200 - 206
• Main Authors: Cholette, Jill M, Mamikonian, Lara, Alfieris, George M, Blumberg, Neil, Lerner, Norma B
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ltd 01.09.2010; Elsevier
• Subjects: Administration, Oral; Administration, Rectal; Aspirin; Aspirin - administration & dosage; Aspirin - therapeutic use; Biological and medical sciences; Biomarkers - blood; Biomarkers - urine; Blood and lymphatic vessels; C-reactive protein; C-Reactive Protein - analysis; Cardiac surgery; Cardiac Surgical Procedures - adverse effects; Cardiology. Vascular system; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Drug Resistance; Fibrinolytic Agents - administration & dosage; Fibrinolytic Agents - therapeutic use; Heart Defects, Congenital - blood; Heart Defects, Congenital - surgery; Hematology, Oncology and Palliative Medicine; Humans; Infant; Infant, Newborn; Inflammation; Inflammation Mediators - blood; Logistic Models; Medical sciences; New York; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests; Platelets; Prospective Studies; Risk Assessment; Risk Factors; Suppositories; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Thrombosis; Thrombosis - blood; Thrombosis - etiology; Thrombosis - prevention & control; Thromboxane B2 - analogs & derivatives; Thromboxane B2 - urine; Time Factors; Treatment Outcome; Up-Regulation; Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels; New York; C-reactive protein; ARU; University of Rochester; post-operative day; wrCRP; Cardiac surgery; wide range C-reactive protein; thromboxane A 2; aspirin response unit; cardiopulmonary bypass; FVIII; UR; Aspirin; POD; uTxB 2; urinary 11-dehydrothromboxane B 2; cyclooxygenase; Inflammation; COX; Thrombosis; sCD40L; CPB; TxA 2; Platelets; factor VIII; soluble CD40 ligand; Human; Prostaglandin-endoperoxide synthase; Enzyme; Enzyme inhibitor; Cardiovascular disease; Acetylsalicylic acid; Antiplatelet agent; Vascular disease; Non steroidal antiinflammatory agent; Platelet; Analgesic; Surgery; Antipyretic; Oxidoreductases; Salicylates; C reactive protein; Child
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2010.05.017

Abstract Introduction Aspirin is often used to prevent thrombosis in pediatric cardiac surgery. The primary study aim was to assess aspirin resistance in this context. Secondary aims were to evaluate (1) the relationship between elevated inflammatory markers and thrombosis and (2) aspirin's effect on these levels. Materials and Methods This was a prospective observational study of children undergoing cardiac surgery managed with and without aspirin. Aspirin response was assessed using the VerifyNow™ system and urinary 11-dehydrothromboxane B2 (uTxB2 ) measurements. Laboratory studies of inflammation were also obtained. Results 101 subjects were studied; 50 received aspirin. Six subjects (5.9%), 5 aspirin-treated, experienced symptomatic thrombosis. When measured by VerifyNow™ resistance was 43% after aspirin suppositories and 14% after additional days of oral aspirin. There was no correlation with thrombosis. Upper quartile post-operative day (POD) #5 uTxB2 was correlated with thrombosis in aspirin treated subjects (p < 0.01). High risk aspirin-treated subjects who experienced thrombosis had higher POD#5 uTxB2. This finding did not reach statistical significance (p = 0.07). Elevated pre-operative C-reactive protein (CRP) was independently associated with thrombosis (p < 0.02) in all subjects and in high risk subjects (p = 0.01). Inflammatory markers were not affected by aspirin. Conclusions Aspirin inhibited ex-vivo platelet function with a low incidence of resistance. Elevated POD#5 uTxB2 and pre-operative CRP were correlated with thrombosis in aspirin treated subjects. Further studies are needed to determine whether children with high levels of uTxB2 despite aspirin therapy and/or those with elevated preoperative CRP are at increased risk for thrombosis.